Immunotherapy before and after surgery improves outcomes in head and . . . The addition of immunotherapy prior to surgery requires a robust multidisciplinary approach “The value of multidisciplinary care in head and neck cancer becomes even more important with this approach of providing immunotherapy prior to surgery,” Haddad said
Therapeutic Advancement in Head and Neck Cancer - Oncology Central Immunotherapy has shown promise for HNSCC patients when delivered perioperatively, both before and after standard of care treatment Administered early, when the tumor burden is higher, immunotherapy can enhance the immune response and begin targeting and killing tumor cells
Landmark Phase III Trial Shows Keytruda Significantly Improves Event . . . Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades
Immunotherapy Boosts Head, Neck Cancer Surgery Outcomes Dana-Farber Brigham Cancer Center-led phase 3 clinical trial shows that pembrolizumab before and after standard-of-care surgery significantly extends event-free survival, representing the first advance for these patients in over 20 years BOSTON, April 27, 2025 — Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and
FDA Greenlights Immunotherapy for Advanced Head and Neck Cancer FDA approves immune checkpoint inhibitor drug for patients with resectable locally advanced head and neck cancer, backed by Dana-Farber research FDA decision establishes pembrolizumab as first new standard-of-care treatment for patients with locally advanced head and neck cancer in more than 20 years
Immunotherapy Enhances Head and Neck Cancer Surgery Outcomes Immunotherapy before and after surgery improves outcomes in head and neck cancer Dana-Farber Brigham Cancer Center-led phase 3 clinical trial shows that pembrolizumab before and after standard-of-care surgery significantly extends event-free survival, representing the first advance for these patients in over 20 years Patients with locally advanced head and neck cancer who received the immune